Samsung BioLogics IPO may raise $2 billion in South Korea's third biggest listing
Samsung BioLogics Co Ltd, a contract manufacturer of biotech drugs for global pharmaceutical firms, said on Tuesday its initial public offering is expected to raise as much as $2 billion in what is set to be South Korea`s third-largest IPO.
Oct 04, 2016, 11:11 AM IST